CG&D
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Miglarese, M. R.
Right arrow Articles by Gibson, N. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Miglarese, M. R.
Right arrow Articles by Gibson, N. W.

Cell Growth & Differentiation, Vol 8, Issue 11 1199-1210, Copyright © 1997 by American Association of Cancer Research


ARTICLES

Regulation of fibroblast growth factor 2 expression in melanoma cells by the c-MYB proto-oncoprotein

MR Miglarese, R Halaban and NW Gibson
Department of Cancer, Immunology and Infectious Diseases, Pfizer Central Research, Groton, Connecticut 06340, USA. Mark.Miglarese@quickmail.yale.edu

Dysregulated expression of basic fibroblast growth factor [fibroblast growth factor 2 (FGF-2)] mediates autocrine growth of melanoma cells. The presence of a consensus Myb binding site in the human FGF-2 promoter prompted us to investigate whether this transcription factor could regulate FGF-2 expression in melanomas. We report that c-MYB mRNA is overexpressed in melanoma cell lines compared to normal melanocytes and that ectopic expression of murine c-Myb in SK-MEL-2 human melanoma cells resulted in increased expression of FGF-2 mRNA and FGF-2 protein. Furthermore, murine c-Myb transactivated a reporter plasmid containing the human FGF-2 promoter region in contransfected SK-MEL-2 human melanoma cells. Although a functional DNA-binding domain was required for transactivation, responsiveness to c-Myb was independent of the putative Myb binding site and mapped to two regions of the FGF-2 promoter that did not bind c-Myb in vitro. We suggest that c-MYB contributes to FGF-2-mediated autocrine growth of melanomas by indirectly regulating the FGF-2 promoter.


This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
P. M. Dillon, G. R. Petroni, B. J. Horton, C. A. Moskaluk, P. M. Fracasso, M. G. Douvas, N. Varhegyi, S. Zaja-Milatovic, and C. Y. Thomas
A Phase II Study of Dovitinib in Patients with Recurrent or Metastatic Adenoid Cystic Carcinoma
Clin. Cancer Res., August 1, 2017; 23(15): 4138 - 4145.
[Abstract] [Full Text] [PDF]


Home page
JEMHome page
R. Halaban, E. Cheng, Y. Smicun, and J. Germino
Deregulated E2f Transcriptional Activity in Autonomously Growing Melanoma Cells
J. Exp. Med., March 20, 2000; 191(6): 1005 - 1016.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cell Growth & Differentiation
Copyright © 1997 by the American Association of Cancer Research.